Associate Professor Brett Paterson
Brett Paterson specialises in radiopharmaceutical development: inorganic synthesis, bioconjugation, imaging and therapy
Associate Professor Brett Paterson's research focusses on the development of metal-based targeted radiopharmaceuticals for imaging and therapy. Some radioactive isotopes produce ionising radiation that are suitable for diagnosing and treating disease. Associate Professor Brett Paterson and his team use inorganic/organic chemistry to design and synthesise new targeted radiopharmaceuticals. The team utilises in vitro techniques and advanced molecular imaging to investigate the interplay between molecular structure and function in vivo. Recently, this has involved the development of theranostic radiopharmaceuticals for targeted alpha therapy. Associate Professor Brett Paterson is Head of Radiochemistry at AIBN and the Centre for Advanced Imaging. He received his PhD with Prof Paul Donnelly at the University of Melbourne. His research has been recognised by a Victoria Fellowship in 2011 and a Victorian post-doctoral research fellowship in 2013. Both awards allowed him to conduct research and receive specialist training at King's College London and Boston Children's Hospital/Harvard Medical School. He was awarded an ARC Discovery Early Career Research Award in 2017. Associate Professor Paterson has been a chief investigator on ARC and NHMRC grants and is a co-inventor on three patents.
Industry
Associate Professor Paterson engages with several biomedical companies focusing on radionuclide production and radiopharmaceutical development including Clarity Pharmaceuticals, Telix Pharmaceuticals, Remy Therapeutics and AdvanCell Isotopes.
Collaborations
Associate Professor Paterson collaborates with national and international researchers within the fields of inorganic chemistry and radiopharmaceutical science including Prof Paul Donnelly (University of Melbourne), Prof Kristofer Thurecht, Dr Nick Fletcher and Prof Paul Bernhardt (UQ) and Dr Michelle Ma (King's College London) and researchers at Monash University and Helmholtz-Zentrum Dresden-Rossendorf (HZDR) as part of the ‘Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics’ (MHELTHERA).
Funding
Associate Professor Paterson has been a CI on research grants across various schemes including ARC Discovery and Linkage and an NHMRC investigator grant. He is a CI on the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals and ARC Training Centre for Innovation in Biomedical Imaging Technology.
Key Publications
Paterson, B. M.; Alt, K.; Jeffery, C. M.; Price, R. I.; Jagdale, S.; Rigby, S.; Williams, C. C.; Peter, K.; Hagemeyer, C.E.; Donnelly, P. S., Enzyme-mediated site-specific bioconjugation of metal complexes to proteins: Sortase-mediated coupling of copper-64 to a single-chain antibody. Angewandte Chemie - International Edition 2014, 53 (24), 6115 - 6119.
Lange, J. L.; Davey, P. R. W. J.; Ma, M. T.; White, J. M.; Morgenstern, A.; Bruchertseifer, F.; Blower, P. J.; Paterson, B. M. An octadentate bis(semicarbazone) macrocycle: A potential chelator for lead and bismuth radiopharmaceuticals. Dalton Transactions 2020, 49 (42), 14962 - 14974
Paterson, B. M.; Roselt, P.; Denoyer, D.; Cullinane, C.; Binns, D.; Noonan, W.; Jeffery, C. M.; Price, R. I.; White, J. M.; Hicks, R. J.; Donnelly, P. S. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Transactions 2014, 43 (3), 1386 - 1396
Grieve M. L.; Davey P. R. W. J.; Forsyth C. M.; Paterson, B. M. The synthesis of a bis(Thiosemicarbazone) macrocyclic ligand and the Mn(II), Co(II), Zn(II) and 68Ga(III) complexes. Molecules 2021, 26 (122) 3646
Kelderman, C. A. A.; Maclean, R. C.; Hungnes, I. N.; Davey, P. R. W. J.; Salimova, E.; de Veer, M.; Patel, N; Ma, M. T.; Paterson, B. M. Technetium Nitrido Complexes of Tetradentate Thiosemicarbazones: Kit-Based Radiolabeling, Characterization, and In Vivo Evaluation. Inorganic Chemistry, 2023, 62 (50), 20791 - 20805